BiotechTube
Home/Omnes Therapeutics/Dr. Bart Van Riet
DB

Dr. Bart Van Riet

CEO

Omnes Therapeutics

Therapeutic Areas

Rare Disease

Omnes Therapeutics Pipeline

DrugIndicationPhase
OMN-001Mucopolysaccharidosis type IPreclinical
OMN-002Glycogen storage disease type IIPreclinical
OMN-003Lysosomal acid lipase deficiencyPreclinical

Leadership Team at Omnes Therapeutics

DJ
Dr. Jan De Smet
CSO
DI
Dr. Isabelle Dubois
CFO
View full Omnes Therapeutics profile